



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سلوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





Ain Shams University

Faculty of Pharmacy

Department of Pharmaceutics and Industrial Pharmacy

Topical delivery systems for a natural product

Thesis submitted in partial fulfillment of the requirements for the Master Degree in

Pharmaceutical Sciences

(Pharmaceutics)

By

Bassant Atef Abdel-Hafez Sayed El-Ahl

(Bachelor of Pharmaceutical Sciences, 2014)

Under the supervision of

Prof. Dr. Sabry Sayed Badawy (RIP)

Professor of Pharmaceutics and Industrial Pharmacy

Faculty of Pharmacy

Misr International University

Prof. Dr. Rihab Osman Ahmed

Professor of Pharmaceutics and Industrial Pharmacy

Faculty of Pharmacy

Ain Shams University

Prof. Dr. Rania Aziz Helmy Ishak

Professor of Pharmaceutics and Industrial Pharmacy

Faculty of Pharmacy

Ain Shams University

(2022)

Acknowledgments

First and foremost, thanks to God by the grace of whom this work was achieved.

I was lucky to have supervisors who cared a lot about me and my work.

I would like to express my sincere gratitude to **Prof. Sabry Sayed Badawy (RIP)**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Misr International University, for the great support, valuable guidance, and precious advices.

No word could ever express my deep thanks and gratitude to **Prof. Rihab Osman Ahmed**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for her valuable advices, critical comments, extreme patience; I owe her a lot of gratitude for providing me with a wealth of information and great support.

I am also grateful to **Prof. Rania Aziz Ishak**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, who directed and encouraged me throughout my thesis with her patience and knowledge. I am very thankful for her valuable guidance and supervision.

I would like to express my gratitude to **Prof. Hany Mahmoud**, Head of Pharmaceutics and Industrial pharmacy department, Misr International University, for his great support.

I would like to express my deep thanks to my colleague **Reem Ashraf** for her technical and knowledgeable advice and support.

Finally, my deep and sincere gratitude to **my family** who encouraged and supported me all along.

Bassant Atef
2022

List of contents

List of contents

Item	Page
List of abbreviations	I
List of tables	IV
List of figures	VI
Abstract	XI
General introduction	1
Scope of work	16
Chapter 1: Preparation and optimization of magnolol loaded ufasomes	17
Introduction	17
Experimental	28
1. Materials	28
2. Equipment	29
3. Methodology	30
3.1. Spectrophotometric assay of Mag	30
3.1.1. UV scanning of Mag using UV-visible spectrophotometer	30
3.1.2. Construction of Mag calibration curve in different media	30
3.2. HPLC assay of Mag	30
3.3. Preparation of plain ufasomes	31
3.3.1. Preliminary optimization studies for the preparation of plain ufasomes	32
3.3.1.1. Effect of buffer type	32
3.3.1.2. Effect of hydration timing	32

3.3.1.3. Effect of the rounded flask capacity	32
3.3.1.4. Effect of fatty acid concentration	33
3.3.1.5. Effect of surfactant type	33
3.3.1.6. Effect of Span® 80 concentration	33
3.3.1.7. Effect of HDA as a novel fatty acid	33
3.4. Preparation of Mag-loaded ufasomes	33
3.5. Optimization of Mag loaded ufasomal formulations	34
3.6. Characterization of the prepared ufasomes	37
3.6.1. PS and PDI measurements	37
3.6.2. Zeta potential (ZP) determination	38
3.6.3. Determination of Mag encapsulation efficiency (EE)	38
3.6.4. Examination by transmission electron microscope (TEM)	39
3.6.5. Differential Scanning Calorimetry (DSC) analysis	39
3.7. <i>In vitro</i> drug release study	39
3.8. <i>Ex vivo</i> skin permeation and deposition studies	40
3.8.1. Preparation of rat skin	40
3.8.2. Skin permeation studies	40
3.8.3. Drug skin deposition studies	42
3.9. Physical stability study of Mag-ufasomes dispersions	42
3.10. Statistical analysis	42
3.10.1. Point prediction and model validation	43
3.10.2. Optimization data analysis	43
4. Results and discussion	44
4.1. Spectrophotometric assay of Mag in different media	44

4.2. HPLC assay of Mag in PBS (pH 7.4) containing 2% Tween® 80 using HPLC	49
4.3. Preparation of ufasomes	51
4.4. Preliminary optimization studies for the preparation of plain ufasomes	52
4.4.1. Effect of buffer type	53
4.4.2. Effect of hydration timing	54
4.4.3. Effect of the rounded flask capacity	54
4.4.4. Effect of oleic acid concentration	55
4.4.5. Effect of surfactant type	55
4.4.6. Effect of Span®80 Concentration	56
4.4.7. Effect of HDA as a novel fatty acid forming HDA vesicles	57
4.5. Preparation of Mag-loaded ufasomes according to Box-Behnken design	59
4.5.1. Model generation	59
4.5.2. Model diagnostics	62
4.5.3. Data analysis	66
4.5.3.1. PS response	66
4.5.3.2. ZP response	76
4.5.3.3. EE response	80
4.5.4. Model validation	82
4.5.5. Optimization analysis	82
4.6. Characterization of the optimized ufasomes	87
4.6.1. Differential Scanning Calorimetry (DSC)	87
4.6.2. TEM imaging	89
4.7. <i>In vitro</i> drug release studies	89
4.8. <i>Ex-vivo</i> skin permeation studies	93
4.9. Skin deposition studies	96
4.10. Physical stability study	97

Conclusions	100
Chapter 2: Preparation and characterization of organogel formulations for topical delivery of magnolol loaded ufasomes.	101
Introduction	101
Experimental	107
1. Materials	107
2. Equipment	107
3. Methodology	108
3.1. Preparation of plain lecithin organogels (OG)	108
3.2. Preparation of Mag loaded OG formulations	108
3.3. Characterization of the prepared OG	109
3.3.1. Organoleptic properties	109
3.3.1.1. Physical examination	109
3.3.1.2. Consistency test	109
3.3.2. pH determination	109
3.3.3. Drug content analysis	109
3.3.4. Evaluation of gel characteristics	110
3.3.4.1. Determination of gel transition temperature	110
3.3.4.2. Determination of gelation time	110
3.3.4.3. Spreadability test	110
3.3.5. Rheological studies	111
3.3.6. Differential scanning calorimetry (DSC)	111
3.3.7. Scanning electron microscope (SEM)	112
3.4. <i>In vitro</i> drug release studies	112
3.5. <i>Ex vivo</i> skin permeation and deposition studies	112
3.6. Statistical analysis	113

4. Results and discussion	114
4.1. Preparation of plain and Mag loaded OG formulations	114
4.2. Characterization of the prepared OG formulations	114
4.2.1. Organoleptic properties	114
4.2.2. pH and drug content analysis	114
4.2.3. Gel characteristics	115
4.2.3.1. Gel transition temperature	115
4.2.3.2. Gelation time	116
4.2.3.3. Spreadability	116
4.2.4. Rheological studies	117
4.2.5. DSC	121
4.2.6. SEM Imaging of gel microstructures	122
4.3. <i>In vitro</i> drug release studies	125
4.4. <i>Ex-vivo</i> skin permeation studies	130
4.5. Skin deposition studies	135
Conclusions	139

Chapter 3: *In vivo* anti-cancer evaluation of magnolol loaded ufasomes and organogel formulations.

Introduction	141
Experimental	147
1. Materials	147
2. Equipment	147
3. Animals	147
4. Methodology	148
4.1. <i>In vivo</i> anticancer evaluation	148

4.1.1. Animal model	148
4.1.2. Tumor induction using DMBA.	149
4.1.3. Treatment with the selected Mag-loaded formulations	149
4.1.4. Assessment of mice body weight	150
4.1.5. Measurements of tumor size and number of papillomas	150
4.2. Determination of malondialdehyde (MDA) and glutathione (GSH) levels in skin tumor samples	151
4.3. Immunohistochemistry (Ki-67 expression) analysis	151
4.4. Histopathological examinations	152
4.5. Statistical analysis	152
5. Results and discussion	153
5.1. Mice body weight	153
5.2. Tumor size and number of papillomas	154
5.3. MDA and GSH levels in skin tumor samples	162
5.4. Immunohistochemistry (Ki-67 expression) analysis	165
5.5. Histopathological examinations	170
Conclusions	181
General conclusions	183
Future perspectives	184
Summary	185
References	192
Appendix I	
Ethical approval for <i>in vivo</i> studies	
Appendix II	
Published review article	
Arabic summary	

List of Abbreviations

List of abbreviations

Abbreviation	Designation
α -MNG	α -mangostin
5-FU	5-flurouracil
AG	Ammonium glycyrrhizinate
AgNPs	Silver nanoparticles
ANOVA	Analysis of variance
BCC	Basal cell carcinoma
BSA	Bovine serum albumin
CLO	Clotrimazole
Conc	Concentration
Cur	Curcumin
DEX	Dexamethasone
DSC	Differential scanning calorimetry
DMBA	7,12- dimethylbenz(a)anthracene
EE	Entrapment efficiency
EMT	Epithelial-mesenchymal transitions
FLU	Fluconazole
GSH	Glutathione
HDA	10-Hydroxy decanoic acid
h	Hour
IC50	50% inhibitory concentration

LDH	Lactate dehydrogenase
LDC	Lidocaine
m-Cur	Monoketonic curcuminoid
ME	Microemulsion
MDA	Malondialdehyde
MTT	((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
Mag	Magnolol
NE	Nanoemulsion
NLCs	Nanostructured lipid carriers
NMSC	Non-melanoma skin cancer
NPs	Nanoparticles
OA	Oleic acid
OAV	Oleic acid vesicles
OCT	Optical coherence tomography
OG	Organogel
PBS	Phosphate buffer solution
PS	Particle size
PDI	Polydispersity index
PpIX	Protoporphyrin IX
PTX	Paclitaxel
PL90G	90% Soya phosphatidylcholine
PLN	PEGylated lipid nanocarriers

PLO	Pluronic lecithin organogel
RA	Rheumatoid arthritis
RCM	Reflectance confocal microscopy
ROS	Reactive oxygen species
Rpm	Rotation per minute
SAA	Surface active agent
SEM	Scanning electron microscope
SC	Stratum corneum
SCC	Squamous cell carcinoma
SSD	Silver Sulphadiazin
TEM	Transmission electron microscope
TER	Terbinafine
UF	Ufasomes
UV	Ultraviolet
Vs	Versus
ZP	Zeta potential

List of Tables